Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Pembrolizumab yielded durable responses in patients with advanced Merkel cell carcinoma

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.04.16
Views: 2013
Rating:

Dr Paul Nghiem - University of Washington, Seattle, USA

Dr Paul Nghiem speaks with ecancertv at AACR 2016 about his research to treat MCC, a virally induced cancer, using pembrolizumab.

The Merkel cell polyoma virus can inhabit human skin, infecting a site in childhood and not become pathogenic until decades later, leading to Dr Nghiem describing the likelihood that its reawakening is caused by immune quiescence in later age.

Reversing this immune suppression with pembrolizumab is reported as an effective treatment, and helps to re-established host immunity as potent even after the age of 65.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation